Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Country Selector Country Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV711 Mouse Anti-Human CD43
      Product Details
      Down Arrow Up Arrow


      BD OptiBuild™
      Leukosialin; LSN; Galactoglycoprotein; GALGP; GPL115; SPN; Sialophorin
      Human (Tested in Development)
      Mouse IgG1, κ
      Activated Human T Cells
      Flow cytometry (Qualified)
      0.2 mg/ml
      IV N601; V AS297
      AB_2742991
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV711 under optimal conditions that minimize unconjugated dye and antibody.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. This antibody was developed for use in flow cytometry.
      2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      3. Researchers should determine the optimal concentration of this reagent for their individual applications.
      4. An isotype control should be used at the same concentration as the antibody of interest.
      5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      9. BD Horizon Brilliant Violet 711 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
      10. Cy is a trademark of GE Healthcare.
      11. Alexa Fluor® is a registered trademark of Life Technologies Corporation.
      Show More blue down arrow Show Less blue up arrow
      745447 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      L60

      The L60 monoclonal antibody specifically binds to CD43 which is also known as Leukosialin (LSN) or Galactoglycoprotein (GALGP). CD43 is a ~95-135 kDa heavily O-sialylated type I transmembrane glycoprotein that is encoded by SPN (sialophorin) and belongs to the cell surface mucin family. The L60 antibody recognizes a sialic acid-dependent determinant on CD43. CD43 is highly expressed on T lymphocytes, thymocytes, monocytes, granulocytes, bone marrow stem cells, pre-B cells and activated B cells plasma cells but not on resting peripheral blood B cells, red blood cells, and non-hematopoietic cells. CD43 is enzymatically shed from leucocyte surfaces following activation by various stimuli. CD43 appears to be involved in mediating intercellular interactions that regulate leucocyte functions.

      The antibody was conjugated to BD Horizon™ BV711 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 711-nm.  BD Horizon BV711 can be excited by the violet laser and detected in a filter used to detect Cy™5.5 / Alexa Fluor® 700-like dyes (eg, 712/20-nm filter).  Due to the excitation and emission characteristics of the acceptor dye, there may be moderate spillover into the Alexa Fluor® 700 and PerCP-Cy5.5 detectors.  However, the spillover can be corrected through compensation as with any other dye combination.

      745447 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BV711
      The BD Horizon Brilliant Violet™ 711 (BV711) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 713-nm. BV711, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 710-nm (e.g., a 712/20-nm bandpass filter). The acceptor dye can be excited by the Red (628–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV711
      Violet 405 nm
      407 nm
      713 nm
      745447 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "745447" on CiteAb

      Development References (15)

      1. Ardman B, Sikorski MA, Staunton DE. CD43 interferes with T-lymphocyte adhesion. Proc Natl Acad Sci U S A. 1992 June; 89(11):5001-5005. (Clone-specific: Flow cytometry, Functional assay, Immunoprecipitation, Radioimmunoassay). View Reference
      2. Bazil V, Strominger JL. CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes. Proc Natl Acad Sci U S A. 1993 May; 90(9):3792-3796. (Biology). View Reference
      3. Campanero MR, Pulido R, Alonso JL, et al. Down-regulation by tumor necrosis factor-alpha of neutrophil cell surface expression of the sialophorin CD43 and the hyaluronate receptor CD44 through a proteolytic mechanism. Eur J Immunol. 1991 December; 21(12):3045-3048. (Biology). View Reference
      4. Cyster JG, Williams AF. The importance of cross-linking in the homotypic aggregation of lymphocytes induced by anti-leukosialin (CD43) antibodies. Eur J Immunol. 1992 October; 22(10):2565-2572. (Biology). View Reference
      5. Kuijpers TW, Hoogerwerf M, Kuijpers KC, Schwartz BR, Harlan JM. Cross-linking of sialophorin (CD43) induces neutrophil aggregation in a CD18-dependent and a CD18-independent way. J Immunol. 1992 August; 149(3):998-1003. (Biology). View Reference
      6. Ngan BY, Picker LJ, Medeiros LJ, Warnke RA. Immunophenotypic diagnosis of non-Hodgkin's lymphoma in paraffin sections. Co-expression of L60 (Leu-22) and L26 antigens correlates with malignant histologic findings.. Am J Clin Pathol. 1989; 91(5):579-83. (Clone-specific: Immunohistochemistry). View Reference
      7. Park JK, Rosenstein YJ, Remold-O'Donnell E, Bierer BE, Rosen FS, Burakoff SJ. Enhancement of T-cell activation by the CD43 molecule whose expression is defective in Wiskott-Aldrich syndrome. Nature. 1991 April; 350(6320):706-709. (Biology). View Reference
      8. Rieu P, Porteu F, Bessou G, Lesavre P, Halbwachs-Mecarelli L. Human neutrophils release their major membrane sialoprotein, leukosialin (CD43), during cell activation. Eur J Immunol. 1992 November; 22(11):3021-3026. (Biology). View Reference
      9. Rosenstein Y, Park JK, Hahn WC, Rosen FS, Bierer BE, Burakoff SJ. CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1.. Nature. 1991; 354(6350):233-5. (Biology). View Reference
      10. Segal GH, Stoler MH, Tubbs RR. The "CD43 only" phenotype. An aberrant, nonspecific immunophenotype requiring comprehensive analysis for lineage resolution. Am J Clin Pathol. 1992 June; 97(6):861-865. (Biology). View Reference
      11. Stefanova I, Hilgert I, and Horejsi V. Studies of the CD43 panel antibodies. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:608.
      12. Stoll M, Dalchau R, Schmidt RE. Cluster report: CD43. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:604-608.
      13. Stross WP, Flavell DJ, Flavell SU, et al. Epitope specificity and staining properties of CD43 (sialophorin) antibodies. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:615.
      14. Stross WP, Warnke RA, Flavell DJ, et al. Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen.. J Clin Pathol. 1989; 42(9):953-61. (Clone-specific: Western blot). View Reference
      15. Wieczorek R, Buck D, Bindl J, Knowles DM. Monoclonal antibody Leu-22 (L60) permits the demonstration of some neoplastic T cells in routinely fixed and paraffin-embedded tissue sections.. Hum Pathol. 1988; 19(12):1434-43. (Immunogen: Immunohistochemistry). View Reference
      View All (15) View Less
      745447 Rev. 1

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.